Revenue from the digital biomarkers market is expected to reach nearly $22 billion by 2030, according to a July 26 report from Prescient and Strategic Intelligence. The market drew revenue of $1.9 ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such ...

Digital devices for collecting patient data — from connected blood pressure monitors to Ginger.io's voice analysis software — are creating a new category of medical data, digital biomarkers. According ...

We reveal health patterns of daily life through patient-centric digital biomarkers – accelerating personalised healthcare and ...

NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable ...

Study shows digital biomarkers from wearables can continuously track cognition and mood, enabling early detection of brain ...

The Digital Biomarker Lab builds on TNO’s expertise in health and behavior measurement and years of experience in digital biomarker development. Projects cover chronic inflammatory, cardiovascular, ...

Digital biomarker to enhance precision, reduce patient burden and boost efficiency of global Phase 2 trial of NEU-411 in early Parkinson's disease SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...

Intermountain Healthcare, Rush University Medical Center and the University of Texas Health Science Center at Houston have joined a study backed by the National Institutes of Health to create an ...

Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for ...